logo
logo

Protai Raises $8 Million Seed Round To Provide A Proteomics-Based Platform For Faster And More Accurate Drug Discovery

Jan 05, 2022•over 3 years ago

Amount Raised

$8 Million

Round Type

seed

Tel Aviv

Description

Protai, an AI-powered drug discovery startup, today announced its emergence from stealth, along with an $8 million seed financing round co-led by Grove Ventures and Pitango HealthTech. The funding will be used to further develop Protai's platform, accelerate its discovery programs and enhance its partnerships with pharmaceutical companies.

Company Information

Company

Protai

Location

Tel Aviv, Tel Aviv District, Israel

About

Protai empowers drug discovery with proteomics and artificial intelligence to unlock new layers of biological insights and to combat complex diseases. Protai's platform has made a leap in solving how drug candidates are created and validated, facilitating quicker and more advanced drug discovery. Protai is backed by mission-driven leading VC funds Grove Ventures and Pitango HealthTech. The Tel Aviv based company was founded by Eran Seger and Kirill Pevzner, both experienced entrepreneurs and tech executives, and alumni of Israeli intelligence cyber corps. Protai's Advisory Board includes world-renowned proteomics and machine learning researchers including, Prof. Tami Geiger, an expert in cancer proteomics research at the Weizmann Institute of Science, Professor Alexey Nesvizhskii, a global leader in computational proteomics from the University of Michigan and Prof. Avi Ma'ayan, the Director of the Mount Sinai Center for Bioinformatics at the Icahn School of Medicine at Mount Sinai, and an expert in the application of machine learning for drug discovery.